Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

Overview

Journal Brain Sci

Publisher MDPI

Date 2022 Oct 27

PMID 36291224

Authors

Nawal Alsubaie

Hayder M Al-Kuraishy

Ali I Al-Gareeb

Bandar Alharbi

Michel De Waard

Jean-Marc Sabatier

Hebatallah M Saad

Gaber El-Saber Batiha

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) was used to describe pre-senile dementia to differentiate it from senile dementia, which develops in the adult age group of more than 65 years. AD is characterized by the deposition of amyloid beta (Aβ) plaque and tau-neurofibrillary tangles (TNTs) in the brain. The neuropathological changes in AD are related to the deposition of amyloid plaques, neurofibrillary tangles, and progression of neuroinflammation, neuronal mitochondrial dysfunction, autophagy dysfunction, and cholinergic synaptic dysfunction. Statins are one of the main cornerstone drugs for the management of cardiovascular disorders regardless of dyslipidemia status. Increasing the use of statins, mainly in the elderly groups for primary and secondary prevention of cardiovascular diseases, may affect their cognitive functions. Extensive and prolonged use of statins may affect cognitive functions in healthy subjects and dementia patients. Statins-induced cognitive impairments in both patients and health providers had been reported according to the post-marketing survey. This survey depends mainly on sporadic cases, and no cognitive measures were used. Evidence from prospective and observational studies gives no robust conclusion regarding the beneficial or detrimental effects of statins on cognitive functions in AD patients. Therefore, this study is a narrative review aimed with evidences to the beneficial, detrimental, and neutral effects of statins on AD.

Citing Articles

Autophagy modulators in type 2 diabetes: A new perspective.

Zaidalkilani A, Al-Kuraishy H, Fahad E, Al-Gareeb A, Elewa Y, Zahran M J Diabetes. 2024; 16(12):e70010.

PMID: 39676616 PMC: 11647182. DOI: 10.1111/1753-0407.70010.

Under-Prescription of Drugs in the Elderly Population of Western Romania: An Analysis Based on STOPP/START Version 2 Criteria.

Baneu P, Prelipcean A, Buda V, Jianu N, Tudor A, Andor M J Clin Med. 2024; 13(19).

PMID: 39408034 PMC: 11477657. DOI: 10.3390/jcm13195970.

Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.

Ali N, Al-Kuraishy H, Al-Gareeb A, Hadi N, Assiri A, Alrouji M Cell Mol Neurobiol. 2024; 44(1):55.

PMID: 38977507 PMC: 11230952. DOI: 10.1007/s10571-024-01489-y.

The role of statins in amyotrophic lateral sclerosis: protective or not?.

Al-Kuraishy H, Jabir M, Sulaiman G, Mohammed H, Al-Gareeb A, Albuhadily A Front Neurosci. 2024; 18:1422912.

PMID: 38903602 PMC: 11188367. DOI: 10.3389/fnins.2024.1422912.

Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.

Alrouji M, Al-Kuraishy H, Al-Gareeb A, Alshammari M, Alexiou A, Papadakis M J Cell Mol Med. 2024; 28(11):e18412.

PMID: 38842132 PMC: 11154839. DOI: 10.1111/jcmm.18412.

References

Mendez M . Early-onset Alzheimer Disease and Its Variants. Continuum (Minneap Minn). 2019; 25(1):34-51. PMC: 6538053. DOI: 10.1212/CON.0000000000000687. View

Al-Kuraishy H, Al-Gareeb A, Al-Buhadilly A . Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases. 2018; 6(1). PMC: 5871955. DOI: 10.3390/diseases6010009. View

Algotsson A, Winblad B . Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins. Dement Geriatr Cogn Disord. 2004; 17(3):109-16. DOI: 10.1159/000076342. View

Wood W, Eckert G, Igbavboa U, Muller W . Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta. 2003; 1610(2):281-90. DOI: 10.1016/s0005-2736(03)00025-7. View

Eckert G, Kirsch C, Mueller W . Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport. 2001; 12(5):883-7. DOI: 10.1097/00001756-200104170-00003. View

Chen M, Hong C, Yue T, Li H, Duan R, Hu W . Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy. Theranostics. 2021; 11(5):2395-2409. PMC: 7797673. DOI: 10.7150/thno.47408. View

Sano M, Bell K, Galasko D, Galvin J, Thomas R, van Dyck C . A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011; 77(6):556-63. PMC: 3149154. DOI: 10.1212/WNL.0b013e318228bf11. View

Suraweera C, de Silva V, Hanwella R . Simvastatin-induced cognitive dysfunction: two case reports. J Med Case Rep. 2016; 10:83. PMC: 4822314. DOI: 10.1186/s13256-016-0877-8. View

Leduc V, De Beaumont L, Theroux L, Dea D, Aisen P, Petersen R . HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Mol Psychiatry. 2014; 20(7):867-73. PMC: 4318698. DOI: 10.1038/mp.2014.81. View

10.

Alomair B, Al-Kuraishy H, Al-Gareeb A, Al-Hamash S, De Waard M, Sabatier J . Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals (Basel). 2022; 15(9). PMC: 9500901. DOI: 10.3390/ph15091147. View

11.

Sharma A, Pachauri V, Flora S . Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease. Front Pharmacol. 2018; 9:1247. PMC: 6249274. DOI: 10.3389/fphar.2018.01247. View

12.

Eckert G, Wood W, Muller W . Statins: drugs for Alzheimer's disease?. J Neural Transm (Vienna). 2005; 112(8):1057-71. DOI: 10.1007/s00702-004-0273-1. View

13.

Bitzur R . Remembering Statins: Do Statins Have Adverse Cognitive Effects?. Diabetes Care. 2016; 39 Suppl 2:S253-9. DOI: 10.2337/dcS15-3022. View

14.

Shepherd J, Blauw G, Murphy M, Cobbe S, Bollen E, Buckley B . The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 1999; 84(10):1192-7. DOI: 10.1016/s0002-9149(99)00533-0. View

15.

Wang M, Qin L, Tang B . MicroRNAs in Alzheimer's Disease. Front Genet. 2019; 10:153. PMC: 6405631. DOI: 10.3389/fgene.2019.00153. View

16.

Posvar E, Radulovic L, Cilla Jr D, Whitfield L, Sedman A . Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996; 36(8):728-31. DOI: 10.1002/j.1552-4604.1996.tb04242.x. View

17.

Sun Y, Crisby M, Lindgren S, Janciauskiene S . Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Abeta(1-42) in glioma cell culture in vitro. Pharmacol Res. 2003; 47(2):119-26. DOI: 10.1016/s1043-6618(02)00288-8. View

18.

Jick H, Zornberg G, Jick S, Seshadri S, Drachman D . Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31. DOI: 10.1016/s0140-6736(00)03155-x. View

19.

Al-Thomali A, Al-Kuraishy H, Al-Gareeb A, K Al-Buhadiliy A, De Waard M, Sabatier J . Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke. Biomedicines. 2022; 10(8). PMC: 9405641. DOI: 10.3390/biomedicines10082032. View

20.

Ostrowski S, Wilkinson B, Golde T, Landreth G . Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007; 282(37):26832-26844. DOI: 10.1074/jbc.M702640200. View